InvestorsHub Logo
Post# of 26891
Next 10
Followers 437
Posts 42954
Boards Moderated 2
Alias Born 05/08/2006

Re: None

Wednesday, 06/24/2020 3:13:51 PM

Wednesday, June 24, 2020 3:13:51 PM

Post# of 26891
Compensated Awareness Post View Disclaimer
QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Results from 2020 Annual and Special Meeting

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced the results of the 2020 Annual and Special Meeting (the “Meeting”). According to the update, the Meeting was held at 1:00 p.m. (Pacific Time) on June 23, 2020, whereby there were 47,819,789 shares of the Company represented in person or by proxy, constituting 53.38% of the Company’s issued share capital as at May 13, 2020, being the record date of the Meeting. All of the proposals are described in detail in the Company’s proxy statement filed with the Securities Exchange Commission via Edgar and with the BC Securities Commission and Ontario Securities Commission via SEDAR on May 25, 2020.

To view the full press release, visit http://ibn.fm/YPpAR

About Lexaria
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.